1
Subsequent 48?2 h [1]. The prevalence of HAE is unclear; however, it is estimated to affect 1 in 50,000?00,000 individuals globally [4?]. The onset of symptoms typically begins during childhood; symptoms often worsen during puberty, and HAE attacksgenerally continue throughout the life of the patient [1]. HAE episodes usually occur without a predictable trigger; however, attacks can be precipitate
1
Subsequent 48?2 h [1]. The prevalence of HAE is unclear; however, it is estimated to affect 1 in 50,000?00,000 individuals globally [4?]. The onset of symptoms typically begins during childhood; symptoms often worsen during puberty, and HAE attacksgenerally continue throughout the life of the patient [1]. HAE episodes usually occur without a predictable trigger; however, attacks can be precipitate
1
Subsequent 48?2 h [1]. The prevalence of HAE is unclear; however, it is estimated to affect 1 in 50,000?00,000 individuals globally [4?]. The onset of symptoms typically begins during childhood; symptoms often worsen during puberty, and HAE attacksgenerally continue throughout the life of the patient [1]. HAE episodes usually occur without a predictable trigger; however, attacks can be precipitate
1
Distinct scenarios (the input variables are independent or in network connection).To attain this objective, we applied logistic regression, neural network, and Bayesian network around the distinctive datasets.MethodSimulation studiesSimulation research had been conducted to evaluate the performance on the logis.Distinct scenarios (the input variables are independent or in network relationship).To
1
Of action. This is often an iterative process in which analytical similarity is tested and then further explored in preclinical biofunctional tests to determine whether minor differences, should they exist, result in differences in the biological activity of the molecule (Fig. 1). Confidence in the similarity of the molecule at this foundational step allows for a reduction in residual uncertainty
1
Of action. This is often an iterative process in which analytical similarity is tested and then further explored in preclinical biofunctional tests to determine whether minor differences, should they exist, result in differences in the biological activity of the molecule (Fig. 1). Confidence in the similarity of the molecule at this foundational step allows for a reduction in residual uncertainty
1
Oma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-a: structure, function and interaction with anti-TNF agents. Rheumatology. 2010;49(7):1215?8. Rosales C, Uribe-Querol E. Fc receptors: cell activators of antibody functions. Adv Biosci Biotechnol. 2013;4:21?3. van der Poel CE, Spaapen RM, van de Winkel JGJ, Leusen JHW. Functional characteristics of the high affinity IgG receptor, FcgRI.
1
An DD, Ho V, Meibohm B, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals. 2014;42(4):177?3. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014;124(22): 3191?. Ebbers HC. Biosimilars: in support of extrapolation of indications. J Crohns Colitis. 2014;8(5):431?. Liu J, et al. Assessing analytical si